PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22842957-0 2013 Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Nateglinide 91-102 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 22842957-2 2013 Our objective was to assess the association between CYP2C9 and SLCO1B1 polymorphisms and the metabolism of nateglinide in healthy Chinese male volunteers. Nateglinide 107-118 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-58 22842957-6 2013 CYP2C9*3 and 521 T>C polymorphisms were the significant predictors of the AUC(0- ) and CL/F of nateglinide (adjusted multiple R(2) = 34 % and 43 %, respectively) according to multiple linear regression analyses, but they have no significant association with changes in the blood glucose-lowering effect of nateglinide. Nateglinide 98-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 22842957-7 2013 CONCLUSIONS: Both SLCO1B1 521 T>C and the CYP2C9*3 polymorphisms can significantly affect the pharmacokinetics of nateglinide, but they could only partially explain the interindividual variability of plasma concentration of nateglinide. Nateglinide 117-128 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 45-51 17253883-8 2007 In addition to CYP3A4, repaglinide is metabolised via CYP2C8, while nateglinide metabolism also involves CYP2C9. Nateglinide 68-79 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 105-111 20809476-7 2010 Fluvastatin and nifedipine increased the systemic exposure of nateglinide in rabbits, probably due to their inhibitory action on the metabolism of nateglinide by CYP2C5 (human CYP2C9). Nateglinide 62-73 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 176-182 20809476-7 2010 Fluvastatin and nifedipine increased the systemic exposure of nateglinide in rabbits, probably due to their inhibitory action on the metabolism of nateglinide by CYP2C5 (human CYP2C9). Nateglinide 147-158 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 176-182 20609060-1 2010 OBJECTIVES: Nateglinide is metabolized by CYP2C9 and CYP3A4, therefore drug-drug interactions through cytochrome P450 (CYP) inhibition may occur. Nateglinide 12-23 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 42-48 20609060-4 2010 KEY FINDINGS: The results showed that nateglinide inhibited CYP2C9 and CYP2C19 with an IC50(app) (apparent value of the 50% inhibitory concentration) of 125 micromol/l and 946 micromol/l, respectively, while M1 did not inhibit any of the CYP isoforms. Nateglinide 38-49 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 60-66 20609060-5 2010 The inhibition constant (K(i)) value of the inhibitory effect of nateglinide on CYP2C9 and the 1 + I(in,max,u)/K(i) value were estimated (where I(in,max,u)= the maximum unbound concentration of nateglinide). Nateglinide 65-76 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 80-86 20609060-7 2010 The influence of pre-incubation on the inhibition by nateglinide of CYP3A4, CYP2C9 and CYP2C19 was examined. Nateglinide 53-64 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 76-82 18159128-1 2007 Nateglinide is an antidiabetic agent metabolized by CYP2C9 and CYP3A4; hence inhibitors of these CYP isozymes may interact with nateglinide. Nateglinide 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-58 18159128-1 2007 Nateglinide is an antidiabetic agent metabolized by CYP2C9 and CYP3A4; hence inhibitors of these CYP isozymes may interact with nateglinide. Nateglinide 128-139 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-58 15005635-11 2004 Pharmacokinetic-pharmacodynamic modelling revealed a minor effect of CYP2C9 genotype on insulin and glucose, and extrapolations indicated that carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycaemia compared with carriers of CYP2C9*1, particularly when taking nateglinide doses above 120 mg. Nateglinide 291-302 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 159-165 16042675-3 2005 Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metabolized by CYP2C9 and CYP3A4. Nateglinide 161-172 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 198-204 16372821-10 2005 The meglitinide-class drug nateglinide is metabolised by CYP2C9. Nateglinide 27-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 57-63 16372821-11 2005 According to the pharmacokinetic data, moderate dose adjustments based on CYP2C9 genotypes may help in reducing interindividual variability in the antihyperglycaemic effects of nateglinide. Nateglinide 177-188 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 74-80 15197517-0 2004 Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. Nateglinide 66-77 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 22-28 15197517-1 2004 PURPOSE: The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on the pharmacokinetics of nateglinide (Starlix), a novel antidiabetic drug which is primarily (approximately 70%) metabolized via CYP2C9. Nateglinide 162-173 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 90-96 15197517-1 2004 PURPOSE: The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on the pharmacokinetics of nateglinide (Starlix), a novel antidiabetic drug which is primarily (approximately 70%) metabolized via CYP2C9. Nateglinide 162-173 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 266-272 15197517-1 2004 PURPOSE: The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on the pharmacokinetics of nateglinide (Starlix), a novel antidiabetic drug which is primarily (approximately 70%) metabolized via CYP2C9. Nateglinide 175-182 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 90-96 15197517-1 2004 PURPOSE: The objective of the study was to determine the effect of a potent and selective CYP2C9 inhibitor, sulfinpyrazone (Anturane), on the pharmacokinetics of nateglinide (Starlix), a novel antidiabetic drug which is primarily (approximately 70%) metabolized via CYP2C9. Nateglinide 175-182 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 266-272 15005635-0 2004 Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Nateglinide 72-83 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 15005635-2 2004 According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6. Nateglinide 41-52 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 92-117 15005635-7 2004 RESULTS: Significantly reduced oral nateglinide clearance was found in carriers of CYP2C9*3 alleles, (p < 0.01), whereas carriers of CYP2C9*2 alleles had kinetic parameters similar to those of carriers of the wild-type allele (p = nonsignificant). Nateglinide 36-47 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 83-89 15005635-10 2004 These differences in nateglinide kinetics due to CYP2C9 genotypes did not result in statistically significant differences in plasma glucose, insulin and glucagon. Nateglinide 21-32 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 14741071-1 2004 OBJECTIVE: The potential for a drug interaction was investigated between nateglinide, an oral antidiabetic agent, and acenocoumarol, an oral anticoagulant, as these drugs are primarily metabolized via CYP2C9. Nateglinide 73-84 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 201-207 14748619-7 2004 Nateglinide is extensively metabolised, primarily by cytochrome P450 2C9, and eliminated primarily by the kidney. Nateglinide 0-11 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 53-72 15005635-11 2004 Pharmacokinetic-pharmacodynamic modelling revealed a minor effect of CYP2C9 genotype on insulin and glucose, and extrapolations indicated that carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycaemia compared with carriers of CYP2C9*1, particularly when taking nateglinide doses above 120 mg. Nateglinide 291-302 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 159-165 15005635-12 2004 CONCLUSION: The effect of CYP2C9 polymorphisms on nateglinide kinetics may cause a slightly increased risk for hypoglycaemia, which may become relevant in diabetic patients. Nateglinide 50-61 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 26-32 29375004-8 2019 Predicted contributions of CYP3A4 and CYP2C9 to nateglinide metabolism were 8.18-37.84% and 36.08-94.04%, separately. Nateglinide 48-59 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 38-44